F Triebel

Inserm FR

Publications

496

Citations

H-Index

i10-Index

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

T cell major histocompatibility complex class II molecules down‐regulate CD4<sup>+</sup> T cell clone responses following LAG‐3 binding

Bertrand Huard, Philippe Prigent, Franck Pagès, Denis Bruniquel, F Triebel

European Journal of Immunology 1996

133

A unique V-J-C-rearranged gene encodes a gamma protein expressed on the majority of CD3+ T cell receptor-alpha/beta- circulating lymphocytes. OA

F Triebel, Florence Faure, M Graziani, S Jitsukawa, Marie‐Paule Lefranc +1 more

The Journal of Experimental Medicine 1988

132

Analysis of T-cell immune response in renal cell carcinoma: Polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity

Eric Angevin, Florence Kremer, Catherine Gaudin, Thierry Hercend, F Triebel

International Journal of Cancer 1997

In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.

Catherine Gaudin, P.-Y. Dietrich, S Robache, Maryvonne Guillard, Bernard Escudier +4 more

PubMed 1995

Evidence for expression of two distinct T cell receptor <i>beta</i> -chain transcripts in a human diphtheria toxoid-specific T cell clone.

F Triebel, Richard Breathnach, M Graziani, Thierry Hercend, Patrice Debré

The Journal of Immunology 1988

Publications

12 total

255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization OA

F. Duhoux, N. K. Ibrahim, K. Papadamitriou, J. Canon, S. Morales - ESMO Open, 2023

Cited by 1 Semantic Scholar

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

N. Ibrahim, K. Papadamitriou, F. Duhoux, S. Morales Murillo, Mafalda Oliveira - Journal of Clinical Oncology, 2023

Cited by 2 Semantic Scholar

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

Bernard Doger de Speville, E. Felip, M. Forster, M. Majem, P. Bajaj - Journal of Clinical Oncology, 2023

Cited by 13 Semantic Scholar

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors OA

M. Majem, M. Forster, M. Krebs, J. Peguero, T. Clay - Journal of Thoracic Oncology, 2023

Cited by 10 Semantic Scholar

675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma OA

I. Braña, V. Cheshuk, C. Kristensen, M. E. Ortega, B. Sautois - Regular and Young Investigator Award Abstracts, 2022

Cited by 1 Semantic Scholar

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC OA

M. Forster, M. Krebs, M. Majem, J. Peguero, T. Clay - Journal of Thoracic Oncology, 2022

Cited by 3 Semantic Scholar

1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II) OA

W. Iams, E. Felip, M. Majem, B. Doger, T. Clay - Late-Breaking Abstracts, 2022

Cited by 3 Semantic Scholar

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts OA

M. Krebs, M. Majem Tarruella, M. Forster, J. Peguero, T. Clay - Annals of Oncology, 2022

Cited by 3 Semantic Scholar

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

E. Felip, M. Majem, B. Doger, T. Clay, E. Carcereny - Journal of Clinical Oncology, 2022

Cited by 21 Semantic Scholar

171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer OA

F. Marmé, H. Wildiers, L. Dirix, A. Armstrong, E. de Cuypere - Annals of Oncology, 2022

Cited by 2 Semantic Scholar

Research Topics

CAR-T cell therapy research (5) T-cell and B-cell Immunology (4) Cancer Immunotherapy and Biomarkers (4) Immune Cell Function and Interaction (4) Hematopoietic Stem Cell Transplantation (3)

Frequent Co-Authors

Thierry Hercend

9 joint publications

Eric Angevin

4 joint publications

Anne Caignard

4 joint publications

PY Dietrich

3 joint publications

Catherine Genevée

3 joint publications

JL Pico

3 joint publications

Affiliations

Inserm

FR 1997 - 1992

Institut Gustave Roussy

FR 1997 - 1988

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers

F Triebel

Publication & Citation Trends

Most Cited Works

Publications

255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization OA

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors OA

675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma OA

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC OA

1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II) OA

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts OA

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer OA

Research Topics

Frequent Co-Authors

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back